Topical methotrexate in dermatology: a review of the literature

• Published in: The Journal of dermatological treatment Vol. 33; no. 1; pp. 512 - 517
• Main Authors: Aickara, Divya, Bashyam, Arjun M., Pichardo, Rita O., Feldman, Steven R.
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 02.01.2022
• Subjects: Dermatologic Agents - therapeutic use; Dermatology; Humans; Methotrexate - therapeutic use; Mycosis Fungoides - drug therapy; psoriasis; Psoriasis - drug therapy; Skin Neoplasms - drug therapy; Topical methotrexate; topical therapy; treatment; treatment; Topical methotrexate; topical therapy; psoriasis
• ISSN: 0954-6634; 1471-1753
• DOI: 10.1080/09546634.2020.1770170

Systemic methotrexate (MTX) is a useful treatment for many dermatologic conditions, however, the risk of adverse events prevents its use in patients with minimal or localized disease. Topical application of MTX may be an option to avoid the systemic adverse effects of oral MTX. To assess what is known about the efficacy and safety of topical methotrexate. A search on Pubmed was conducted. There were no limits on publication date. A total of 963 articles were discovered. Using our exclusion criteria, 916 articles were excluded; 47 articles were used for full text assessment. Topical MTX has been used primarily in psoriasis but also in mycosis fungoides, lymphomatoid papulosis, and oral precancerous lesions. Optimal delivery system and formulation for adequate penetration is still under investigation. The quality of evidence for the utility of topical methotrexate in psoriasis is good, however, for other dermatologic diseases, the quality is poor. Topical MTX with improved delivery methods may be a viable tool against certain localized dermatologic conditions for patients who do not tolerate oral MTX. Further double-blinded randomized controled studies are needed to substantiate the utility of topical methotrexate.